ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Effect of TTH on the Incidence of (MACE) and Efficacy Measures in HG Men
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 143005" data-attributes="member: 13851"><p><a href="https://clinicaltrials.gov/ct2/show/NCT03518034" target="_blank"><strong>A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )</strong> - Full-Text View - ClinicalTrials.gov</a></p><p></p><p></p><p><strong>Brief Summary:</strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.</span></strong></p><p></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Study Design</strong></span></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Study Type</span>:</strong> <strong><em>Interventional (Clinical Trial)</em></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">Estimated Enrollment: </span></strong><em><strong>6000 participants</strong></em></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Allocation: </span><em>Randomized</em></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">Intervention Model: </span><em>Parallel Assignment</em></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">Masking:</span></strong> <em><strong>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</strong></em></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Primary Purpose: </span></strong><em><strong>Treatment</strong></em></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Official Title: </span><em>Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study</em></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">Actual Study Start Date: </span><em>May 3, 2018</em></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">Estimated Primary Completion Date: </span>June 30, 2022</strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">Estimated Study Completion Date: </span>June 30, 2022</strong></p></blockquote><p></p>
[QUOTE="madman, post: 143005, member: 13851"] [SIZE=26px][B] [/B][/SIZE][URL='https://clinicaltrials.gov/ct2/show/NCT03518034'][B]A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )[/B] - Full-Text View - ClinicalTrials.gov[/URL] [B]Brief Summary: [COLOR=rgb(184, 49, 47)]This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.[/COLOR][/B] [COLOR=rgb(0, 0, 0)][B]Study Design[/B][/COLOR] [B][COLOR=rgb(184, 49, 47)]Study Type[/COLOR]:[/B] [B][I]Interventional (Clinical Trial)[/I] [COLOR=rgb(184, 49, 47)]Estimated Enrollment: [/COLOR][/B][I][B]6000 participants[/B][/I] [B][COLOR=rgb(184, 49, 47)]Allocation: [/COLOR][I]Randomized[/I] [COLOR=rgb(184, 49, 47)]Intervention Model: [/COLOR][I]Parallel Assignment[/I] [COLOR=rgb(184, 49, 47)]Masking:[/COLOR][/B][COLOR=rgb(184, 49, 47)][B][I] [/I][/B][/COLOR][I][B]Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)[/B][/I] [B][COLOR=rgb(184, 49, 47)]Primary Purpose: [/COLOR][/B][I][B]Treatment[/B][/I] [B][COLOR=rgb(184, 49, 47)]Official Title: [/COLOR][I]Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study[/I] [COLOR=rgb(184, 49, 47)]Actual Study Start Date: [/COLOR][I]May 3, 2018[/I] [COLOR=rgb(184, 49, 47)]Estimated Primary Completion Date: [/COLOR]June 30, 2022 [COLOR=rgb(184, 49, 47)]Estimated Study Completion Date: [/COLOR]June 30, 2022[/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Effect of TTH on the Incidence of (MACE) and Efficacy Measures in HG Men
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top